Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk

American Journal of Transplantation

Volumn 3, Issue 12, 2003, Pages 1488-1500

  Gebel, Howard M ^a   Bray, Robert A ^a   Nickerson, Peter ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ANTIBODY TITER; B LYMPHOCYTE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE CROSSMATCH; MICROPARTICLE ENZYME IMMUNOASSAY; PLASMAPHERESIS; PREOPERATIVE EVALUATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TREATMENT CONTRAINDICATION;

ANTIBODIES; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; RISK FACTORS; TISSUE DONORS;

EID: 0346121399     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00273.x     Document Type: Review

References (123)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
2. Iwaki Y, Terasaki PI. Primary non-function in human cadaver kidney transplantation: evidence for hidden hyperacute rejection. Clin Transplant 1987; 1: 125.
3. Amos DB, Bashir H, Bogle W et al. A simple microtoxicity test. Transplantation 1970; 7: 220-223.
4. Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of preformed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215-226.
5. Ting A, Hasegawa T, Ferrone S, Reisfeld RA. Presensitization detected by sensitive crossmatch tests. Transplant Proc 1973; 5: 813-817.
6. Cross DE, Whittier FC, Weaver P, Foxworth J. A comparison of the antiglobulin versus extended incubation time crossmatch results in 223 renal transplants. Transplant Proc 1977; 9: 1803-1806.
7. Fuller TC, Cosimi AB, Russell PS. Use of an antiglobulin-ATG reagent for detection low levels of alloantibody-improvement of allograft survival in presensitized recipients. Transplant Proc 1978; 10: 463-466.
8. Fuller T, Phelan D, Gebel H, Rodey C. The antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocyte-toxicity test. Transplantation 1982; 34: 24-29.
9. Kerman RH, Kimball PM, Van Buren CT et al. AHG and DTE/AHG procedure identification of cross-match-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991; 51: 316-320.
10. Fuller TC, Fuller AA, Golden M, Rodey GE. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. Hum Immunol 1997; 56: 94-105.
11. Gebel HM, Oldfather JW, Karr RW, Rodey GE. Antibodies directed against HLA-DR gene products exhibit the CYNAP phenomenon. Tissue Antigens 1984; 23: 135-140.
12. Garovoy MR, Rheinschmilt MA, Bigos M et al. Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15: 1939-1944.
13. Chapman JR, Deierhoi MH, Carter NP et al. Analysis of flow cytometry and cytotoxicity crossmatches in renal transplantation. Transplant Proc 1985; 17: 2480-2481.
14. Bray RA, Lebeck LK, Gebel HM. The flow cytometric crossmatch: dual color analysis of T cell and B cell reactivities. Transplantation 1989; 48: 834-840.
15. Scornik JC, Brunson ME, Schaub B et al. The crossmatch in renal transplantation. Transplantation 1994; 57: 621-625.
16. Scornik JC, Bray RA, Pollack MS et al. Multicenter evaluation of the flow cytometry T-cell crossmatch. Transplantation 1997; 63: 1440-1445.
17. Scornik JC, Clapp W, Patton PR et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001; 71: 1098-1102.
18. Cross DE, Greiner R, Whittier FC. Importance of the autocontrol crossmatch in human renal transplantation. Transplantation 1976; 21: 307-311.
19. Ting A, Morris PJ. Renal transplantation and B-cell crossmatches with autoantibodies and alloantibodies. Lancet 1977; 2: 1095-.
20. Ettenger RB, Jordan SC, Fine RN. Cadaver renal transplant outcome in recipients with autolymphocytotoxic antibodies. Transplantation 1983; 35: 429-431.
21. Pettaway CA, Freeman CC, Helderman HJ, Stastny P. Kidney transplant recipients with long incubation-positive, antiglobulin-negative T-cell cross-matches. Transplantation 1987; 44: 529-533.
22. Chapman JR, Taylor CJ, Ting A, Morris PJ. Immunoglobulin class and specificity antibodies causing positive T cell crossmatches: Relationship to renal transplant outcome. Transplantation 1986; 42: 608-613.
23. Iwaki Y, Lau M, Terasaki PI. Successful transplants across T warm-positive crossmatches due to IgM antibodies. Clin Transplant 1988; 2: 81-84.
24. Taylor CJ, Chapman JR, Ting A, Morris PJ. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989; 48: 953-958.
25. Barocci S, Valente U, Gusmano R et al. Autoreactive lymphocytotoxic IgM antibodies in highly sensitized dialysis patients waiting for a kidney transplant: identification and clinical relevance. Clin Nephrol 1991; 36: 12-20.
26. Vaidya S, Ruth J. Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation 1989; 47: 956-958.
27. Barger B, Shroyer TW, Hudson SL et al. Successful renal allografts in recipients with cross-match-positive, dithioerythritol-treated negative sera. Transplantation 1989; 47: 240-244.
28. Bryan CF, Martinez J, Muruve N et al. IgM antibodies identified by a DTT-ameliorated positive cross-match do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin Transplantation 2001; 15 (Suppl. 6): 28-35.
29. Zachary AA, Delaney NL, Lucas DP, Leffell MS. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets. I. Evaluation of the GTI QuikID assay and analysis of antibody patterns. Hum Immunol 2001; 62: 228-235.
30. Zachary AA, Ratner LE, Graziani JA et al. Characterization of HLA Class II specific antibodies by ELISA using solubilized antigen targets. II. Clinical relevance. Hum Immunol 2001; 62: 236-246.
31. Pei R, Wang G, Tarsitani C et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 5: 313-322.
32. Pei R, Lee J-H, Shih N-J, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antibody specificities. Transplantation 2003; 75: 43-49.
33. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 2000; 69: 1370-1374.
34. McCalmon RT, Spees EK, Tardif GN et al. Successful kidney transplantation in the presence of IgM alloantibodies. Clin Transplant 1991; 5: 255-259.
35. Roelen DL, van Bree J, Witvliet MD et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation 1994; 57: 1388-1392.
36. McCalmon RT, Tardif GN, Sheehan MA et al. IgM antibodies in renal transplantation. Clin Transplant 1997; 11: 558-564.
37. Thistlethwaite JR, Buckingham MR, Stuart JK et al. T cell immunofluorescence flow cross-match results in cadaver donor renal transplantation. Transplant Proc 1987; 19: 722-724.
38. Iwaki Y, Cook DJ, Terasaki P et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 1987; 19: 764-766.
39. Cook DJ, Terasaki PI, Iwaki Y et al. An approach to reducing early kidney transplant failure by flow cytometry crossmatching. Clin Transplant 1987; 1: 253-256.
40. Lazda VA, Pollak R, Mozes MF, Jonasson O. The relationship between flow cytometer crossmatch results and subsequent rejection episodes in cadaver renal allograft recipients. Transplantation 1988; 45: 562-565.
41. Talbot D, Givan AL, Shenton BK et al. The relevance of a more sensitive crossmatch assay to renal transplantation. Transplantation 1989; 47: 552-555.
42. Mahoney RJ, Ault KA, Given SR et al. The flow cytometric crossmatch and early renal transplantation. Transplantation 1990; 49: 527-535.
43. Kerman RH, Van Buren CT, Lewis RM et al. Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation 1990; 49: 52-56.
44. Berteli AJ, Daniel V, Mohring K et al. Association of kidney graft failure with a positive flow cytometric crossmatch. Clin Transplantation 1992; 6: 31-34.
45. Ogura K, Terasaki PI, Johnson C et al. The significance of a positive flow cytometric crossmatch test in primary renal transplantation. Transplantation 1993; 56: 294-298.
46. Christiaans MH, Overhof R, ten Haaft et al. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 1996; 15: 1341-1347.
47. Mahoney RJ, Norman DJ, Colombe BW et al. Identification of high-and low-risk second kidney grafts. Transplantation 1996; 61: 1349-1355.
48. LeFor WM, Ackermann JRW, Alveranga DY et al. Flow cytometry crossmatching and primary cadaver kidney graft outcome: relevance of T and B cell targets, historic sera and autologous controls. Clin Transplant 1996; 10: 601-606.
49. Utzig MJ, Blumke M, Wolff-Vorbeck G et al. Flow cytometry cross-match: a method for predicting graft rejection. Transplantation 1997; 63: 551-554.
50. Pelletier RP, Orosz CG, Adams PW et al. Clinical and economic impact of flow cytometry crossmatching in primary cadaveric kidney and simultaneous pancreas-kidney transplant recipients. Transplantation 1997; 63: 1639-1645.
51. Kimball P, Rhodes C, King A et al. Flow cross-matching identifies patients at risk for postoperative elaboration of cytotoxic antibodies. Transplantation 1998; 65: 444-446.
52. Bryan CF, Baier KA, Nelson PW et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998; 66: 1827-1832.
53. Kerman RH, Susskind B, Buyse I et al. Flow cytometry-detected IgG is not a contra indication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855-1858.
54. El Fettouh HA, Cook DJ, Bishay E et al. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation. Urology 2000; 56: 369-372.
55. O'Rourke RW, Osorio RW, Freise CE et al. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin Transplant 2000; 14: 167-173.
56. Karpinski M, Rush DR, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807-2814.
57. Gebel HM, Bray RA, Ruth JA et al. FlowPRA to detect clinically relevant HLA antibodies. Transplant Proc 2001; 33: 477.
58. Kerman R, Gebel H, Bray R et al. HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Am J Transplant 2002; 2: 258.
59. Cho YW, Cecka JM. Cross-match tests - an analysis of UNOS data from 1991 to 2000. In: Terasaki C, ed. Clinical Transplants. UCLA Immunogenetics Center, Los Angeles, CA 2001: 237-246.
60. Martin S, Dyer PA, Mallick NP et al. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50-53.
61. Scornik JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW. Posttransplant antidonor antibodies and graft rejection: evaluation by two-color flow cytometry. Transplantation 1989; 47: 287-290.
62. Suciu-Foca N, Reed E, D'Agati VD et al. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593-601.
63. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
64. Davenport A, Younie ME, Parsons JEM, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is assoicated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994; 9: 1315-1319.
65. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphcytotoxin. Trans-plantation 1995; 59: 357-360.
66. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kid Int 1996; 50: 1464-1475.
67. Abe M, Kawai T, Futatsuyama K et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation 1997; 63: 1616-1619.
68. Monteiro F, Buelow R, Mineiro C, Rodrigues H, Kalil J. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 1997; 63: 542-546.
69. Utzig MJ, Blumke M, Wolff-Vorbeck G, Lang H, Kirste G. Flow cytometry cross-match: a method for predicting graft rejection. Transplantation 1997; 63: 551-554.
70. Kerman RH, Sussikund B, Kerman DH et al. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Transplantation Proc 1997; 29: 1515-1516.
71. Christiaans MHL, Overhof-de Roos R, Nieman F et al. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65: 427-433.
72. Piazza A, Adorno D, Poggi E et al. Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation. Transplantation Proc 1998; 30: 1769-1771.
73. McKenna R, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
74. Muller-Steinhardt M, Fricke L, Kirchner H, Hoyer J, Kluter H. Monitoring of anti-HLA class I and II antibodies by flow cytometry in patients after first cadaveric kidney transplantation. Clin Transplantation 2000; 14: 85-89.
75. Supon P, Constantino D, Hao P et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001; 71: 577-580.
76. Piazza A, Poggi E, Borrelli L et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106-1112.
77. Pelletier RP, Hennessy PK, Adams PW et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134-141.
78. Baldwin WM, Halloran PF. Clinical syndromes associated with antibody in allografts. In: Racusen LC, Solez K, Burdick JF, eds. Kidney Transplant Rejection: Diagnosis and Treatment, 3rd edn. New York: Marcel Dekker Inc., 1998: 127-147.
79. Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992; 54: 839-843.
80. Ettinger RB, Terasaki PI, Opelz G et al. Successful renal allografts across a positive cross-match for donor B-lymphocyte alloantigens. Lancet 1976; 1: 56-58.
81. Ting A, Morris PJ. Renal transplantation and B-cell crossmatches with autoantibodies and alloantibodies. Lancet 1977; 2: 1095-1097.
82. Sirchia G, Mercuriali F, Scalamogna M et al. Pre-existent anti-HLA-DR antibodies and kidney graft survival. Transplantation Proceedings 1979; 11: 950-953.
83. Ayoub G, Park MS, Terasaki PI, Opelz G. B cell antibodies and crossmatching. Transplantation 1980; 29: 227-229.
84. Mohanakumar T, Rhodes C, Mendez-Picon et al. Renal allograft rejection associated with presensitization to HLA DR antigens. Transplantation 1981; 31: 93-95.
85. Jeannet M, Benzonana G, Arni I. Donor specific B and T lymphocyte antibodies and kidney graft survival. Transplantation 1981; 31: 160-163.
86. Ladza VA, Pollack R, Mozes MF, Jonasson O. Positive B cell crossmatches in highly sensitized patients - influence of antibody specificity on renal transplant outcome. Transplant Proc 1987; 19: 782-784.
87. Russ GR, Nicholls C, Sheldon A, Hay J. Positive B lymphocyte crossmatch and glomerular rejection in renal transplant recipients. Transplant Proc 1987; 19: 785-788.
88. Noreen HJ, van der Hagen E, Bach FH et al. Renal allograft survival in CSA-treated patients with positive donor-specific B cell crossmatches. Transplant Proc 1989; 21: 691-692.
89. Phelan DL, Rodey GE, Flye MW et al. Positive B cell crossmatches: specificity of antibody and graft outcome. Transplant Proc 1989; 21: 687-688.
90. Karuppan SS, Lindholm A, Moller E. Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients. Transplantation 1990; 49: 510-515.
91. Scornik JC, LeFor WM, Cicciarelli JC et al. Hyperacute and acute kidney graft rejection due to antibodies against B cells. Transplantation 1992; 54: 61-64.
92. ten Hoor GM, Coopmans M, Allebes WA. Specificity and Ig Class of preformed alloantibodies causing a positive crossmatch in renal transplantation. Transplantation 1993; 56: 298-304.
93. Ladza VA. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch. Transplantation 1994; 57: 964-969.
94. Ghasemian SR, Light JA, Currier CB et al. The significance of the IgG anti-B-cell crossmatch on renal transplantation outcome. Clin Transplant 1997; 11: 485-487.
95. Bittencourt MC, Rebibou J-M, Saint-Hillier Y et al. Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Nephrol Dial Transplant 1998; 13: 2059-2064.
96. Lobashevsky AL, Senkbeil RW, Shoaf J et al. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000; 14: 533-542.
97. Mahoney RJ, Taranto S, Edwards E. B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63: 324-335.
98. Lazda VA, Rao P, Reed EF et al. The importance of B cell screening and crossmatching for anti-HLA class II antibodies in organ transplantation. In: ASHI Guidelines for Clinical Histocompatibility Practices, 1999: 20-23.
99. Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum Immunol 1989; 26: 245-260.
100. Zachary AA, Hart JM. Relevance of antibody screening and crossmatching in solid organ transplantation. In: Leffell MS, Donnenberg AD, Rose NR, eds. Handbook of Hum Immunol. New York: CRC Press, 1997: 477-520.
101. Bray RA, Sinclair DA, Wilmoth-Hosey et al. Significance of the flow cytometric PRA in the evaluation of patients awaiting renal transplantation. Hum Immunol 1998; 59: 121.
102. Pellegrino M, Belvedere M, Pellegrino AG, Ferrone S. B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. Transplantation 1978; 25: 93-95.
103. Le Bas-Bernardet S, Hourmant M, Valentin N et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75: 477-482.
104. Vaidya S, Cooper TY, Avandsalehi J et al. Improved flow cytometric detection of HLA alloantibodies using pronase. Transplantation 2001; 71: 422-428.
105. Cardella CJ, Falk JA, Nicholson MJ et al. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet 1982; 2: 1240-1243.
106. Sanfilippo F, Vaughn WK, Spees EK, Bollinger RR. Cadaveric renal transplantation ignoring peak reactive sera in patients with markedly decreasing pretransplant sensitization. Transplantation 1984; 38: 119-124.
107. Matas AJ, Nehlsen-Cannarella S, Tellis VA et al. Successful kidney transplantation with current-sera-negative/historical-sera-positive T-cell crossmatch. Transplantation 1984; 37: 111-112.
108. Rosenthal JT, Rabin B, Taylor RJ et al. Positive T cell crossmatch with stored recipient sera in cadaveric renal transplantation. Transplantation 1985; 39: 310-311.
109. Norman DJ, Barry JM, Wetzsteon PJ. Successful cadaver kidney transplantation in patients highly sensitized by blood transfusions. Transplantation 1985; 39: 253-255.
110. Falk JA, Cardella CJ, Halloran P et al. Transplantation can be performed with positive (noncurrent) cross-match. Transplant Proc 1985; 17: 1530-1532.
111. Goeken NE. Outcome of renal transplantation following a positive crossmatch with historical sera: The ASHI survey. Hum Immunol 1985; 14: 77-85.
112. Kerman RH, Flechner SM, Van Buren ET et al. Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. Transplantation 1985; 40: 615-619.
113. Turka L, Goguen JE, Gagne JE, Milford EL. Presensitization and the renal allograft recipient. Transplantation 1989; 47: 234-240.
114. Bryan CF, Shield CF, Warady BA et al. Influence of an historically positive cross-match on cadaveric renal transplantation. Transplant Proc 1999; 31: 225-227.
115. Avlonitis VS, Chidambaram V, Manas DM et al. The relevance of donor T cell-directed immunoglobulin G in historic sera in the age of flow cytometry. Transplantation 2000; 70: 1260-1263.
116. Baron C, Pastural M, Lang P et al. Long-term kidney graft survival across a positive historic but negative current sensitized crossmatch. Transplantation 2002; 73: 232-236.
117. Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M. Positive remote crossmatch: Impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003; 75: 501-505.
118. Reed E, Hardy M, Benvenisty A et al. Effect of antiidiotypic antibodies to HLA on graft survival in renal allograft recipients. N Engl J Med 1987; 316: 1450.
119. Kerman RH, Susskind B, Ruth J et al. Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Transplantation 1998; 66: 1833-1834.
120. Matas AJ, Sutherland DE. Kidney transplantation without a final crossmatch. Transplantation 1998; 66: 1835-1836.
121. Taylor CJ, Smith SI, Morgan CH et al. Selective omission of the donor cross-match before renal transplantation. Transplantation 2000; 69: 719-723.
122. Martin S. A potential revolution in pretransplant histocompatibility testing: selective omission of the donor crossmatch. Transplantation 2000; 69: 709-710.
123. Van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MFJ et al. Activated HLA class I-reactive cytotoxic T lymphocytes associated with a positive historical crossmatch predict early graft failure. Transplantation 2002; 74: 1114-1119.